Document Type : Short Communication


1 Associate Professor, Department of Cardiology, Najafabad Branch, Islamic Azad University, Najafabad, Isfahan, Iran

2 Assistant Professor, Department of Gynecology, Najafabad Branch, Islamic Azad University, Najafabad, Isfahan, Iran

3 General Practitioner, Najafabad Branch, Islamic Azad University, Najafabad, Isfahan, Iran


BACKGROUND: In patients with polycystic ovarian syndrome (PCOS), this is now hypothesized that whether increased risk for cardiovascular disorders is related more to obesity than PCOS per se. This study aimed to compare cardiovascular risk factors between the lean and obese women with PCOS.METHODS: This case-control study was conducted on 86 (43 obese and 43 lean) women with PCOS. The presence of overweight and obesity was defined based on the body mass index (BMI) (> 25 kg/m2). The study objectives were first to compare mean levels of cardiovascular laboratory parameters between lean and obese patients with PCOS and then to assess the relationship between obesity indices and these laboratory parameters.RESULTS: Compared to the lean group, the obese group had significantly higher mean fasting blood sugar (FBS) (89.40 ± 10.73 versus 84.09 ± 7.87 mg/dl, P = 0.011), higher mean serum triglyceride (TG) (119.09 ± 60.66 versus 96.86 ± 27.23 mg/dl, P = 0.032), higher mean total cholesterol (147.70 ± 57.38 versus 126.79 ± 35.95 mg/dl, P = 0.045), and also higher mean low-density lipoprotein (LDL) (92.30 ± 13.53 versus 83.77 ± 17.61 mg/dl, P = 0.014). Using the Pearson’s correlation test, positive correlations were found between BMI and waist circumference (WC) indices and study parameters including FBS, serum TG, serum total cholesterol, serum LDL, and also blood pressure (BP).CONCLUSION: Because of higher concentrations of FBS and lipid profiles in obese patients with PCOS and considering obesity as a more important risk factor for coronary artery disease (CAD) than PCOS, it is recommended to assess and monitor cardiovascular risk factors in these population to reduce the risk for cardiovascular disorders and metabolic syndrome. Also, by reducing body weight and normalizing BMI value, the cardiovascular and metabolic risk factors can be modified and prevented. 


  1. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29(2): 181-91.
  2. Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC. PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG 2006; 113(10): 1210-7.
  3. Bajuk Studen K, Jensterle Sever M, Pfeifer M. Cardiovascular risk and subclinical cardiovascular disease in polycystic ovary syndrome. Front Horm Res 2013; 40: 64-82.
  4. Talbott EO, Zborowski JV, Sutton-Tyrrell K, McHugh-Pemu KP, Guzick DS. Cardiovascular risk in women with polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001; 28(1): 111-33, vii.
  5. Wild RA. Long-term health consequences of PCOS. Hum Reprod Update 2002; 8(3): 231-41.
  6. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF, Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88(6): 2562-8.
  7. Guzick DS, Talbott EO, Sutton-Tyrrell K, Herzog HC, Kuller LH, Wolfson SK Jr. Carotid atherosclerosis in women with polycystic ovary syndrome: Initial results from a case-control study. Am J Obstet Gynecol 1996; 174(4): 1224-9.
  8. Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000; 20(11): 2414-21.
  9. Dahlgren E, Janson PO. Polycystic ovary syndrome-long-term metabolic consequences. Int J Gynaecol Obstet 1994; 44(1): 3-8.
  10. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998; 51(7): 581-6.
  11. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: A retrospective cohort study. Clin Endocrinol (Oxf) 2000; 52(5): 595-600.
  12. Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: The missing link between insulin resistance and obesity. Diabetes Metab 2008; 34(1): 2-11.
  13. Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992; 37(2): 119-25.
  14. Holte J, Bergh T, Berne C, Lithell H. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: Relation to anthropometric, endocrine and metabolic variables. Clin Endocrinol (Oxf) 1994; 41(4): 463-71.
  15. Pirwany IR, Fleming R, Greer IA, Packard CJ, Sattar N. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf) 2001; 54(4): 447-53.
  16. Elting MW, Korsen TJ, Schoemaker J. Obesity, rather than menstrual cycle pattern or follicle cohort size, determines hyperinsulinaemia, dyslipidaemia and hypertension in ageing women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2001; 55(6): 767-76.
  17. Roa MB, Arata-Bellabarba G, Valeri L, Velaķzquez-Maldonado E. Relationship between the triglyceride/high-density lipoprotein-cholesterol ratio, insulin resistance index and cardiometabolic risk factors in women with polycystic ovary syndrome. Endocrinol Nutr 2009; 56(2):
  18. -65.